Correlation Between RYOHIN UNSPADR/1 and Takeda Pharmaceutical

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both RYOHIN UNSPADR/1 and Takeda Pharmaceutical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining RYOHIN UNSPADR/1 and Takeda Pharmaceutical into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between RYOHIN UNSPADR1 and Takeda Pharmaceutical, you can compare the effects of market volatilities on RYOHIN UNSPADR/1 and Takeda Pharmaceutical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in RYOHIN UNSPADR/1 with a short position of Takeda Pharmaceutical. Check out your portfolio center. Please also check ongoing floating volatility patterns of RYOHIN UNSPADR/1 and Takeda Pharmaceutical.

Diversification Opportunities for RYOHIN UNSPADR/1 and Takeda Pharmaceutical

0.28
  Correlation Coefficient

Modest diversification

The 3 months correlation between RYOHIN and Takeda is 0.28. Overlapping area represents the amount of risk that can be diversified away by holding RYOHIN UNSPADR1 and Takeda Pharmaceutical in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Takeda Pharmaceutical and RYOHIN UNSPADR/1 is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on RYOHIN UNSPADR1 are associated (or correlated) with Takeda Pharmaceutical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Takeda Pharmaceutical has no effect on the direction of RYOHIN UNSPADR/1 i.e., RYOHIN UNSPADR/1 and Takeda Pharmaceutical go up and down completely randomly.

Pair Corralation between RYOHIN UNSPADR/1 and Takeda Pharmaceutical

Assuming the 90 days trading horizon RYOHIN UNSPADR1 is expected to generate 1.49 times more return on investment than Takeda Pharmaceutical. However, RYOHIN UNSPADR/1 is 1.49 times more volatile than Takeda Pharmaceutical. It trades about 0.09 of its potential returns per unit of risk. Takeda Pharmaceutical is currently generating about 0.12 per unit of risk. If you would invest  2,160  in RYOHIN UNSPADR1 on December 29, 2024 and sell it today you would earn a total of  220.00  from holding RYOHIN UNSPADR1 or generate 10.19% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy98.44%
ValuesDaily Returns

RYOHIN UNSPADR1  vs.  Takeda Pharmaceutical

 Performance 
       Timeline  
RYOHIN UNSPADR/1 

Risk-Adjusted Performance

Modest

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in RYOHIN UNSPADR1 are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile forward-looking signals, RYOHIN UNSPADR/1 may actually be approaching a critical reversion point that can send shares even higher in April 2025.
Takeda Pharmaceutical 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Takeda Pharmaceutical are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile fundamental indicators, Takeda Pharmaceutical may actually be approaching a critical reversion point that can send shares even higher in April 2025.

RYOHIN UNSPADR/1 and Takeda Pharmaceutical Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with RYOHIN UNSPADR/1 and Takeda Pharmaceutical

The main advantage of trading using opposite RYOHIN UNSPADR/1 and Takeda Pharmaceutical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if RYOHIN UNSPADR/1 position performs unexpectedly, Takeda Pharmaceutical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Takeda Pharmaceutical will offset losses from the drop in Takeda Pharmaceutical's long position.
The idea behind RYOHIN UNSPADR1 and Takeda Pharmaceutical pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Other Complementary Tools

Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Fundamental Analysis
View fundamental data based on most recent published financial statements
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance